Patricia Bastick
Cancer Australia(AU)
Publications by Year
Research Areas
Prostate Cancer Treatment and Research, Cancer Treatment and Pharmacology, Cancer survivorship and care, Bladder and Urothelial Cancer Treatments, HER2/EGFR in Cancer Research
Most-Cited Works
- → Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial(2023)177 cited
- → [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial(2024)130 cited
- → Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial(2023)71 cited
- → Randomized Evaluation of Cognitive-Behavioral Therapy and Graded Exercise Therapy for Post-Cancer Fatigue(2017)60 cited
- → Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer(2017)57 cited
- → Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity(2019)51 cited
- → Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients(2017)46 cited
- → Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial(2025)41 cited
- → Use of risk stratification to guide ambulatory management of neutropenic fever(2011)36 cited
- → Cost of cancer care for patients undergoing chemotherapy: The Elements of Cancer Care study(2015)17 cited